Incyte shares drop after FDA approves GSK's competing blood-cancer treatment
Incyte Corp. (INCY) shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC (GSK.LN) blood-cancer treatment, Ojjaara, that will compete with Incyte's Jakafi. The FDA approved Ojjaara for use in patients with myelofibrosis, a rare blood cancer, with anemia. Ojjaara will likely put pressure on uptake of Jakafi as a first-line treatment for myelofibrosis, Truist Securities analysts wrote in a note Friday. The analysts maintained their buy rating on Incyte shares, saying they don't anticipate that Ojjaara will impact Jakafi revenues from two other conditions, polycythemia vera and graft-versus-host disease. Incyte shares have dropped more than 22% in the year to date, while the S&P 500 has gained 15.9%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-18-23 0812ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks